Phaseline

Targets › LOXO1

LOXO1: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout Dec 2026.

Open in Phaseline: the race on LOXO1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Murdoch Childrens Research InstituteIvermectin
Glutamate-gated chloride channel modulator
LOXO1Phase 2Scabies; ItchDec 2026

Conditions

Scabies; Itch (1)

Modalities

small molecule (1)

Companies

Murdoch Childrens Research Institute (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.